Although human immunodeficiency virus-1 (HIV-1) infects quiescent and proliferating CD4
1 lymphocytes, the virus replicates poorly in resting T cells [1] [2] [3] [4] [5] [6] . Factors that block viral replication in these cells might help to prolong the asymptomatic phase of HIV infection 7 ; however, the molecular mechanisms that control this process are not fully understood. Here we show that Murr1, a gene product known previously for its involvement in copper regulation 8, 9 , inhibits HIV-1 growth in unstimulated CD4
1 T cells. This inhibition was mediated in part through its ability to inhibit basal and cytokine-stimulated nuclear factor (NF)-kB activity. Knockdown of Murr1 increased NF-kB activity and decreased IkB-a concentrations by facilitating phospho-IkBa degradation by the proteasome. Murr1 was detected in CD4 1 T cells, and RNA-mediated interference of Murr1 in primary resting CD4
1 lymphocytes increased HIV-1 replication. Through its effects on the proteasome, Murr1 acts as a genetic restriction factor that inhibits HIV-1 replication in lymphocytes, which could contribute to the regulation of asymptomatic HIV infection and the progression of AIDS.
Murr1 is a highly conserved 190-amino-acid protein that does not have any identifiable motifs, and a homozygous deletion in the gene encoding canine Murr1 leads to copper toxicosis in Bedlington terriers 8 . In this study, Murr1 was initially identified in a two-hybrid screen by binding the X-linked inhibitor of apoptosis, a known activator of NF-kB (refs 10, 11 , and E.B., unpublished observations). To study its effect on NF-kB, HIV-1 reporter plasmids with wildtype or mutant (DkB) sites 2 were co-transfected with control or Murr1 expression plasmids in the different cell lines. Murr1 inhibited both basal and tumour necrosis factor (TNF)-a-dependent HIV-1 transcription from the wild-type but not the kB-mutant reporter in Jurkat T-leukaemia and 293T renal epithelial cell lines (Fig. 1a , left and middle panels). In contrast, Murr1 did not substantially inhibit tumour growth factor-b-dependent transcription in HepG2 cells, confirming its specificity (Fig. 1a, right panel) . The kB effect was dose-dependent and observed with other inducers of NF-kB, including interleukin-1 (IL-1) and 12-O-tetradecanoylphorbol-13-acetate (TPA) (Fig. 1b) . Murr1 modulated the expression of endogenous kB-regulated genes: transfection into 293T cells decreased the endogenous cell-surface expression of major histocompatibility complex (MHC) class I, in contrast to CD9, which is independent of NF-kB (Fig. 1c) .
Its site of action in the NF-kB signalling pathway was further defined by co-transfection of different regulators with an NF-kB reporter in Jurkat T cells. Whereas Murr1 inhibited both IKK-1-and IKK-2-induced NF-kB activity (Fig. 1d , middle and right panels), it failed to block RelA-mediated transcription (Fig. 1d, left panel) , indicating that Murr1 might interact downstream of the IkB kinase signalosome. As determined by immunoprecipitation, cotransfected haemagglutinin (HA)-tagged Murr1 and Myc-tagged IKK-2 did not associate in vivo (Fig. 2a, lane 2, left panel) . Although IKK-1 also did not associate with Murr1 (data not shown), an interaction between transfected HA-tagged Murr1 and endogenous IkB-a was readily detected (Fig. 2a, lane 6) . The ankyrin domain of IkB-a was required for association with Murr1, as were amino acids 1-160 of Murr1 ( Supplementary Fig. 1a) .
A polyclonal antibody against Murr1 demonstrated the association between endogenous Murr1 and IkB-a in vivo. RelA antibody immunoprecipitated IkB-a, IkB-b and Murr1 (Fig. 2b, lane 10) . IkB-a antibody also pulled down RelA and Murr1 (Fig. 2b, lane 12) , but the IkB-b antibody did not precipitate Murr1 (Fig. 2b, lane 14) , suggesting that Murr1 interacted preferentially with the NF-kBIkB-a complex. This association was confirmed in vivo by confocal microscopy with fluorescent fusion proteins ( Supplementary  Fig. 1b) , similarly to the pattern of RelA association with IkB-a [12] [13] [14] . The physiological consequences of these interactions were determined by knockdown of endogenous Murr1 in 293T cells using control and Murr1-specific short interfering RNA (siRNA) duplexes. The specificity of two such siRNAs, Murr1-1 and Murr1-2, directed to different Murr1 sequences, was first confirmed by transfecting 293T cells with wild-type or mutant siRNAs along with wild-type or mutant Murr1 complementary DNAs modified at the siRNA target site (Supplementary Fig. 2 ). Transient transfection of Murr1-specific siRNA duplexes downregulated endogenous Murr1 and IkB-a, had little effect on IkB-b, p65 or IKK-2 ( Fig. 3a , left panel), and increased kB-dependent reporter activity (Fig. 3a, right panel) .
To investigate the mechanism of Murr1 action, 293T cells were transfected with a control or Murr1 siRNA. Four days after transfection, cells were treated with the proteasome inhibitor MG132 for 2 h or with vehicle alone and stimulated with TNF-a. Cells depleted of Murr1 showed a decrease in basal IkB-a ( Fig. 3a) and an increase and persistence of phospho-IkB-a in response to stimulation with TNF-a (Fig. 3b, left panel) . This effect was observed in the absence of a proteasome inhibitor, MG132, but not in its presence (Fig. 3b, right panel) , indicating that Murr1 might act similarly to a proteasome inhibitor to enhance and sustain phospho-IkB. Phospho-IkB-a is degraded by ubiquitin-protein conjugates that require three enzymes, which participate in a cascade of ubiquitin transfer reactions: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3). The specificity of protein ubiquitination and 26S proteasome degradation is determined by the E3 enzymes 15 . Skp1/Cul1/b-TrCP1 (F-Box) complexes constitute a class of E3 enzymes that are required for the degradation of phospho-IkBa 16 . The possible association of endogenous Murr1 with Skp1/Cul1/ b-TrCP1 (F-box) complexes was examined. As determined by immunoprecipitation followed by western blotting, Murr1 interacted biochemically with the Cul1 and not the Skp1 component of the E3 ligase complex, in contrast to a denatured negative control (Fig. 3c) . Although Murr1 binds to common constituents of E3 ligase, it nevertheless showed specificity because knockdown did not alter steady-state concentrations of b-catenin, the target of proteasomal degradation of the Wnt signalling pathway (Fig. 3d) . Taken together, these results suggest that Murr1 blocked NF-kB activation through its ability to interact with E3 ligase and inhibit the proteasomal degradation of IkB.
To determine whether Murr1 was detectable in T cells, lymphocytes from normal healthy individuals were examined. Both CD4 þ and CD8
þ cells expressed Murr1, with higher concentrations in CD4 þ cells (Fig. 4a) , raising the possibility that Murr1 might affect HIV-1 replication in these cells. This possibility was examined first by transfection of Murr1 in primary T cells and compared with another inhibitor of NF-kB activation, the IkB super-repressor (IkB-SR). Expression of recombinant Murr1 or IkB-SR inhibited HIV-1 replication in activated T cells similarly relative to controls ( Fig. 4b ; P ¼ 0.02; paired t-test), indicating that Murr1 might inhibit HIV-1 replication comparably to NF-kB inhibitors in primary activated T cells. To determine its effect on HIV-1 replication in resting primary T cells, CD4
þ cells from HIV-1-negative donors were transfected with an siRNA for Murr1 (Murr1-1) or a negative control. To identify transfected cells, siRNAs were mixed with an unrelated fluorescent Cy3-labelled luciferase siRNA at a ratio of 2:1, and more than 30% of cells displayed fluorescence. In Murr1 siRNA-transfected cells, a maximum decrease in Murr1 protein concentration was achieved between 48 and 72 h after electroporation, and these cells did not display T-cell activation markers-CD69, CD25 and HLA-DR-at the time of HIV-1 infection (data not shown). Murr1 siRNA increased dose-dependent HIV-1 replication in primary resting CD4 þ T cells from three separate cell donors ( Fig. 4c ; P ¼ 0.0007, 0.0024 and 0.0014, respectively; paired t-test), implicating Murr1 in the regulation of HIV infection in these cells.
Whereas HIV-1 entry into activated CD4 þ lymphocytes leads to a productive infection 1 , the virus remains latent in resting CD4 þ lymphocytes 17 , existing as a preintegration complex awaiting cell stimulation, which facilitates the transition to productive replication 3, 4, 6, 7, 18 . The molecular mechanisms responsible for HIV-1 latency are not well understood. Among the factors that can activate HIV-1 replication are host transcription factors such as NF-kB (ref. 2) , epigenetic modifications at the site of integration 19 , premature termination of transcription due to the absence of sufficient concentrations of Tat and NF-kB (refs 20, 21) , and inefficient export of RNAs for structural proteins 5 . The roles of these factors in resting CD4 þ T cells are inferred from cell culture experiments and affect viral transcription, translation or RNA transport. Here we show that Murr1 regulates IkB-a turnover, which inhibits the productive HIV-1 infection of resting T lymphocytes. Expression of Murr1 in activated HIV-infected T cells also inhibited virus replication, indicating that it might also have a function in limiting the extent of viral replication, or burst size. NF-kB is sequestered in the cytoplasm by a 450-kDa IkB complex 12, [22] [23] [24] [25] and, after activation of T cells, phosphorylation of IkB-a (ref. 26) in this complex by two inducible kinases, IKK-1 and IKK-2, leads to the subsequent ubiquitination and degradation of IkB-a by the 26S proteasome 27 . Degradation of IkB-a by the proteasome releases NF-kB, which then translocates to the nucleus to stimulate the synthesis of genes involved in immune activation. NF-kB enhances transcription and subsequently recruits several transcriptional activators, including positive transcription elongation factor b, which is ubiquitinated and degraded by the proteasome 28 . Inhibition of proteasomal activity by Murr1, after it rebounds from its initial degradation and after this processive transcription complex has formed, could subsequently stabilize it and enhance transcription. The proteasome, through the ubiquitin E3 ligase complex, is also involved in viral processing and the maturation of Gag 29 . Because Murr1 inhibits proteasomal degradation, it could further block HIV-1 infection by decreasing the proteasome-dependent degradation and maturation of Gag-associated factors required for viral replication, and although Murr1 acts selectively on the NF-kB and not the Wnt signalling pathway (Fig. 3) , it remains possible that it might yet affect other such proteins degraded by the proteasome. Such an example is APOBEC3G, shown recently to associate with a Cul5 E3 ligase 31 . Blocks to viral replication in resting lymphocytes, as well as in cells containing latent provirus, might affect disease progression and viral rebound after the discontinuation of anti-retroviral therapy (reviewed in ref. 7) . A more precise understanding of the molecular regulation of these events might identify novel genetic restriction factors, like Murr1, through which anti-viral drugs might delay the progression of HIV-1 infection to AIDS. 
T-cell purification and transfection
To purify resting T cells, CD4 þ T lymphocytes were isolated from Ficoll-purified peripheral blood mononuclear cells (PBMCs) by negative selection with a CD4 þ T-cell isolation kit containing CD8, CD11b, CD16, CD19, CD36 and CD56 antibodies (Miltenyi Biotech). CD25 þ and HLA-DR þ cells were then removed from this population by using CD69, CD25 and HLA-DR antibodies (Miltenyi Biotech) by negative selection. The purity of the isolated resting T cells was assessed by fluorescence-activated cell sorting (FACS) analysis for CD4, CD69, CD25 and HLA-DR (BD-Pharmingen); 95% of the cells were CD4 þ and there were less than 0.1% of activated T cells as defined by the presence of CD69, CD25 or HLA-DR. Resting CD4 þ T cells ( 10 7 ) were transfected with control or Murr1 siRNA (Dharmacon). For each transfection, 1.2 mM siRNA (800 nM unlabelled siRNA and 400 nM Cy3-labelled siRNA) was used. Transfections were performed with a 2:1 mixture of unlabelled siRNA and Cy3 luciferase. To transfect the resting CD4 þ T cells with siRNA, 10 7 cells were resuspended in 100 ml T-cell Nucleofector reagent and immediately electroporated with the recommended protocol U-14 on the Nucleofector instrument (Amaxa Biosystems). The electroporated cells were washed 4 h after transfection and incubated in 1.5 ml RPMI and infected with HIV-1 48 h after electroporation. FACS analysis was performed with CD69, CD25 and HLA-DR antibodies (BD Pharmingen) to check the activation status of the cells at the time of infection. For plasmid transfections, CD4 þ T lymphocytes isolated from Ficoll-purified PBMCs by negative selection were stimulated with phytohaemagglutinin (10 mg ml 21 ) (Calbiochem) and 40 U ml 21 IL-2 (Peprotech) for 24 h and maintained in 40 U ml 21 IL-2 for 4 days. Cells were then washed to remove IL-2, and 10 7 cells were resuspended in 100 ml T-cell Nucleofector reagent containing 0.5 mg of the respective plasmids and immediately electroporated with recommended protocol T-20 on the Nucleofector instrument. The electroporated cells were washed 12 h after transfection and incubated in 1.5 ml of RPMI supplemented with 40 U ml 21 IL-2 and infected with HIV-1 24 h after electroporation.
HIV-1 infection and flow cytometric analysis for expression of p24-Gag
At 48 h after siRNA transfection or 24 h after plasmid transfection, HIV-1 infection of CD4 þ T lymphocytes was performed in 96-well round-bottomed culture plates by combining 40 ml virus stock with 20 ml CD4 þ T lymphocytes (1.5 £ 10 5 cells). The multiplicity of infection of undiluted virus was ,1.0. After incubation for 2 h at 37 8C, cells were washed twice and continued in culture with indinavir at 1 mM. CD4 þ T lymphocytes were harvested for intracellular p24-Gag staining 48 h after exposure to virus. In brief, cells were stained with anti-CD4-PE and ethidium bromide monoazide (EMA) for 10 min. EMA was cross-linked to the cells by exposure to a bright light source for 15 min. Cells were washed once, fixed and permeabilized with Cytoperm/Cytofix (BD Pharmingen) for 
